From L-R: Latus CSO Jang-Ho Cha, Latus CEO Peter Ghoroghchian and co-founder Beverly Davidson
May 2, 2024 06:30 AM EDTUpdated 10:44 AM
Financing
Startups
Cell/Gene Tx

Ex­clu­sive: Spark co-founder launch­es new CNS gene ther­a­py biotech with $54M

Kyle LaHucik

Senior Reporter

Jang-Ho Cha had no in­ter­est in leav­ing his post at No­var­tis, where he led trans­la­tion­al med­i­cine for the phar­ma gi­ant’s work in neu­ro­science.

But in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times